作者: Takao Hamakubo , Osamu Kusano-Arai , Hiroko Iwanari
DOI: 10.1016/J.BBAPAP.2014.08.007
关键词:
摘要: Abstract The monoclonal antibody has become an important therapeutic in the treatment of both hematological malignancies and solid tumors. recent success antibody-drug conjugates (ADCs) broadened extent potential target molecules cancer immunotherapy. As a result, even low abundance have targets for cytotoxic reagents. multi-pass membrane proteins are emerging next generation therapeutics. One outstanding challenge is difficulty preparing sufficient amount these so as to be able generate functional antibody. We pursued expression various on baculovirus particle utilization displayed protein immunization. strong antigenicity virus acts either friend or foe making efficient against immunologically tolerant antigen. This article part Special Issue entitled: Recent advances molecular engineering